Study of Resveratrol Added to Standard Treatment for Adults with Moderate to High Rheumatoid Arthritis

What this Trial Is About

Researchers are evaluating the effects of resveratrol in adults with moderate to high active rheumatoid arthritis RA. The study aims to understand how resveratrol impacts inflammation, oxidative stress, disease activity, and quality of life in patients already receiving standard RA treatment. The trial is sponsored by Ain Shams University and involves 118 eligible patients randomly assigned to two groups. One group will receive standard RA treatment plus a daily 1 gram dose of resveratrol for three months, while the other group will receive only the standard treatment for the same period. Resveratrol is given as a single 1000 mg tablet once daily. Patients are monitored for 3 months during treatment. Participants will undergo assessments of inflammation and oxidative stress by measuring serum markers such as Sirtuin 1 SIRT1, Myeloperoxidase MPO, and C-reactive protein CRP. Disease activity will be evaluated using the DAS28 score, and quality of life will be measured using the Health Assessment Questionnaire Disability Index HAQ-DI. Researchers will also monitor for any adverse effects related to resveratrol throughout the study period, which lasts from 3 to 6 months.

Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.